AI is changing how drugs are discovered. Making them still depends on slow, expensive trial and error, one experiment and one batch at a time. Ark builds the world model for biomanufacturing, so new medicines reach more patients, sooner.
Built for the hardest problems in bioprocess. Ark is a small team of scientists, modelers and software engineers, most of us with PhDs, building AI that predicts how living cells behave at industrial scale. Pharma brings us the problems it can’t solve in-house.

Co-Founder & CEO
Yossi began his career as a quantitative researcher at Two Sigma, where he saw how modeling changed the financial industry. He started Ark to bring that power to the step where cells become medicine.

Head of Modeling
Nick leads Ark’s modeling team and the work that combines physics with AI at the core of the platform. He holds a PhD in optimization from Carnegie Mellon.

Head of Software
Robert leads the engineering behind Ark’s platform, from the simulation engine to the agents that put it to work.

Co-Founder, Ark Biotech; Former Director of MSAT, Sanofi

Founder & CEO, H1

Robert Steinberg Professor Emeritus of Statistics and Data Science, Wharton

Professor of Biological Systems Engineering, Imperial College

Professor of Applied AI, The University of Manchester

Distinguished Engineer and Former Senior Director of BioProcess Development, Genentech

Co-Founder, National Resilience